Pharmaceutical

EC grants orphan drug designation to Dyne Therapeutics’ DMD therapy

The EC has granted orphan drug designation to Dyne Therapeutics’ DYNE-251 for treating Duchenne muscular dystrophy (DMD).

Apr 26, 2025 - 06:00
EC grants orphan drug designation to Dyne Therapeutics’ DMD therapy
The EC has granted orphan drug designation to Dyne Therapeutics’ DYNE-251 for treating Duchenne muscular dystrophy (DMD).
Read the original article

Tags:

Previous Article

Granite Bio secures $100m in funding for new antibodies

Next Article

Top 20 biopharmas’ market cap rises 6% in Q1 2025 amid tariff headwinds

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Opinion: Listen: Ezekiel Emanuel explains why cancer patients shouldn’t pay out-of-pocket costs

Opinion: Listen: Ezekiel Emanuel explains why cancer pa...

May 31, 2023

STAT+: AbbVie purchases neuroscience developer Cerevel for $8.7 billion

STAT+: AbbVie purchases neuroscience developer Cerevel ...

Dec 7, 2023

STAT+: Medicare details the structure of its new drug price negotiation program

STAT+: Medicare details the structure of its new drug p...

Jun 30, 2023